RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 Docetaxel Added to Anthracycline Regimens Benefits Patients with Highly Proliferative ER-Positive Breast Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 36
SP 13
OP 14
DO 10.1177/155989771436009
UL http://mdc.sagepub.com/content/14/36/13.abstract
AB Adding taxanes to an anthracycline-based chemotherapy regimen in the adjuvant setting has become a standard approach in the management of patients with breast cancer. However, long-term outcomes data are still lacking regarding the safety and efficacy of this approach. This article presents data from the 10-year final safety and efficacy analyses of the Intergroup Phase 3 BIG 2-98 trial [NCT00174655].